ArticleChinese journal of integrative medicine2026
Ginsenoside Rg2 Targeting PDHE1 α to Improve High Glucose-Induced Hippocampal Neuronal Damage Based on CETSA Experiment.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the effect of ginsenoside Rg2 (G-Rg2) targeting pyruvate dehydrogenase E1 component subunit alpha (PDHE1 α) on its downstream energy metabolism to repair damaged hippocampal neurons.
methodsThe binding affinity between G-Rg2 and PDHE1 α was obtained by molecular docking (MD) and surface plasmon resonance (SPR). The thermal stability of Rg2 binding to PDHE1 α protein was evaluated by cellular thermal shift assay (CETSA), and the binding of Rg2 to PDHE1 α protein was further confirmed by isothermal dose-response curve. The mouse hippocampal neuronal cell line (HT22) was divided into 2 main groups: a PDHE1 α transfection control group and a PDHE1 α silencing group. Each main group was further subdivided into 3 treatment groups: a normal group (untreated), a high-glucose injury model group, and a Rg2 adminis0tration group. The downstream molecules and metabolites of PDHE1 α such as adenosine triphosphate (ATP), reactive oxygen species (ROS), acetyl coenzyme A (acetyl-CoA), and the oxidized/reduced ratio of nicotinamide adenine dinucleotide (NAD
resultsMD and SPR techniques found that G-Rg2 directly bound to the target protein PDHE1 α and significantly improved its thermal stability. Isothermal dose-response results were consistent with these findings. The high glucose-induced HT22 cell injury model showed abnormal phenotypes including decreased PDH enzyme activity, increased ROS, decreased ATP production, an imbalanced NAD
conclusionPDHE1 α can be used as a direct cell target for G-Rg2 to treat high glucose-injured neurons, which can provide data support for the protein activity of PDHE1 α and the pharmacological activity of G-Rg2 in improving neurodegenerative diseases.
Indexed as
Identifiers
41920259What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.